Assyro AI

Orange Book product · Brand (NDA)

SPRITAM

LEVETIRACETAM

Brand (NDA)NDA 207958DISCN APRECIA PHARMS

At a glance

Jul 31, 2015

Approved

Brand (NDA)

Application

Not listed

TE code

5

Listed patents

Key dates

  1. Approval

    FDA approval date of this drug product.

    Jul 31, 2015

    11 yr 1 mo ago

  2. Today

  3. Patent 11160786 expires

    Listed drug product patent expiration.

    Mar 14, 2034

    in 7 yr 10 mo

  4. Patent 9339489 expires

    Listed drug product patent expiration.

    Mar 14, 2034

    in 7 yr 10 mo

  5. Patent 9669009 expires

    Listed method-of-use patent (U-1850) expiration.

    Mar 14, 2034

    in 7 yr 10 mo

  6. Patent 9669009 expires

    Listed method-of-use patent (U-2021) expiration.

    Mar 14, 2034

    in 7 yr 10 mo

  7. Patent 9669009 expires

    Listed method-of-use patent (U-2022) expiration.

    Mar 14, 2034

    in 7 yr 10 mo

Pharmaceutical detail

Active ingredient

LEVETIRACETAM

Strength

1GM

Dosage form

TABLET, FOR SUSPENSION

Route

ORAL

TE code

Not listed

Application

NDA 207958

Product number

004

Marketing status

DISCN

Reference listed drug (RLD)

Yes

Reference standard (RS)

No

Active-ingredient family

View full family

This is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

Listed patents (5)

Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
11160786Mar 14, 2034in 7 yr 10 mo
Product
9339489Mar 14, 2034in 7 yr 10 mo
ProductU-1850
9669009Mar 14, 2034in 7 yr 10 mo
U-1850
9669009Mar 14, 2034in 7 yr 10 mo
U-2021
9669009Mar 14, 2034in 7 yr 10 mo
U-2022
Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.